Analysis of the mechanism of action and clinical pharmacological properties of DaliRasheng (Keweike)

Daridorexant is a new type of dual Orexin Receptor Antagonist (DORA), mainly used to treat patients with insomnia. Orexin (Orexin) is a neuropeptide secreted by the hypothalamus and is involved in regulating arousal, energy metabolism and emotional stability. An overactive oresin system can lead to a persistent state of arousal, causing difficulty falling asleep or frequent nighttime awakenings. Dalirasin works by selectively antagonizing the orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R), inhibiting wake signal transduction, thereby promoting sleep initiation and maintenance, and restoring the natural sleep cycle at night.

In terms of clinical pharmacological properties, DaliRasen has the characteristics of rapid onset of action and short half-life . It is absorbed rapidly after oral administration, and peak plasma concentration (Tmax) is usually reached within 30 to 60 minutes after taking the drug, which helps relieve difficulty in falling asleep. At the same time, the half-life of the drug is approximately 8 hours, allowing it to continue to work at night, but the blood concentration decreases when you wake up in the morning, reducing the risk of daytime sleepiness and cognitive function impact. This pharmacokinetic property enables DaliRazen to improve sleep quality while also taking into account safety and maintaining patients' daytime functions.

DaliRasen's Pharmacodynamic properties Mainly reflected in improving sleep latency (sleep onset latency), prolonging total sleep time (total sleep time, TST) and reducing the number of nighttime awakenings. Multiple clinical studies have shown that DaliRasen can significantly improve subjective and objective sleep indicators, and has shown good efficacy in patients with coexisting difficulty falling asleep and night awakenings. In addition, compared with benzodiazepine hypnotics, Dalitraxen has less impact on cognitive function, motor coordination and respiratory function, is less likely to cause dependence, and is safer for long-term use.

In terms of safety and tolerability, common adverse reactions of DaliRazo include dizziness, drowsiness, fatigue, etc., most of which are mild to moderate and can be relieved by themselves. The drug is metabolized by the liver CYP3A4 so caution should be used when combined with strong CYP3A4 inhibitors or inducers to avoid significant increases or decreases in plasma concentrations. DaliRasen does not affectGABAreceptor pathways, so it does not cause dependence or tolerance like traditional benzodiazepines and is less likely to cause falls or next-day cognitive impairment.

To sum up, DaliRasen selectively inhibits arousal signals through dual oresin receptor antagonism mechanism, thereby improving sleep quality. Its rapid onset of action, short half-life and good pharmacokinetic properties make it clinically effective in alleviating difficulty falling asleep and nighttime awakenings, while also reducing the risk of daytime sleepiness and cognitive impairment. At the same time, the high safety and low dependence characteristics of DaliRasen make it an effective and long-term sustainable treatment option for patients with insomnia, providing a new targeted treatment solution for modern sleep disorder management.

Reference materials:https://www.drugs.com/